![Side Effect Cbd Gummies: What To Expect And How To Use Them Safely [IlsblDpwacS]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-7723360-150x150.jpg "Side Effect Cbd Gummies: What To Expect And How To Use Them Safely [IlsblDpwacS] 7")
![Cbd Gummy With Full Spectrum: A Practical Guide For Everyday Wellness [L9wwWLgksjM]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-17605669-150x150.jpg "Cbd Gummy With Full Spectrum: A Practical Guide For Everyday Wellness [L9wwWLgksjM] 8")
![Cbd Gummy Drops: A Practical Look At Convenience, Evidence, And Everyday Use [DTSDrGlBpeu]](https://cedclinic.com/wp-content/uploads/2026/07/ced-pexels-11251712-150x150.jpg "Cbd Gummy Drops: A Practical Look At Convenience, Evidence, And Everyday Use [DTSDrGlBpeu] 18")
#72 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should understand that patients with back pain may be self-substituting cannabis for opioids without disclosure, which limits the ability to assess drug interactions, monitor efficacy, and provide evidence-based guidance on comparative safety and efficacy. This finding highlights the need for direct, non-judgmental screening about cannabis use during pain management discussions, particularly in older adults who may assume clinicians won’t approve of or need to know about cannabis use. Acknowledging cannabis as a potential pain management option and discussing its risks and benefits directly may improve medication reconciliation and shared decision-making in chronic pain care.
A recent study in the Journal of Cannabis Research examined cannabis use patterns among older adults with back pain, finding that fewer than one in five patients disclosed their cannabis use to healthcare providers. The research indicates that some older adults are substituting inhaled cannabis for opioid medications to manage chronic back pain, suggesting a potential harm reduction strategy in an aging population vulnerable to opioid-related adverse effects. However, the low rate of patient-provider communication about cannabis use represents a significant clinical gap, as physicians lack critical information about concurrent substance use that could affect pain management decisions, drug interactions, and overall health monitoring. For clinicians treating older patients with chronic back pain, this underscores the importance of proactively asking about cannabis use in a non-judgmental manner to build trust and maintain comprehensive medication reconciliation. Physicians should counsel patients on the limited evidence base for cannabis in back pain, potential respiratory risks with inhalation, and safer alternative routes of administration if cannabis use is being considered. The practical takeaway is that clinicians must initiate direct conversations about cannabis use during pain assessments to close the disclosure gap and provide evidence-based guidance on pain management options.
“This observational study offers an interesting signal that some patients perceive cannabis as helpful for back pain management, but we need to be cautious about interpreting this as evidence that inhaled cannabis should replace opioids without large randomized trials directly comparing efficacy and safety in this population. The fact that most older adults aren’t discussing cannabis use with their physicians is actually the more pressing clinical concern here, because we need that dialogue to understand drug interactions, assess lung health, and monitor for adverse effects.”
💊 While this observational study suggesting cannabis may replace opioid use in older adults with back pain is potentially encouraging given the opioid crisis, clinicians should interpret these findings cautiously given the lack of randomized controlled trial evidence, unclear causality, and the under-reporting of cannabis use to providers noted in the study itself. The substitution pattern observed does not establish that cannabis is equally effective or safe for chronic pain management, particularly in older adults who face distinct risks including cognitive effects, drug interactions, and fall hazards. Cannabis inhaled acutely may also differ substantially in safety profile and efficacy from pharmaceutical opioids when used chronically for degenerative spine conditions. Practically, this research highlights the importance of actively asking patients about cannabis use rather than waiting for disclosure, and of having evidence-based conversations about risks and benefits of various pain management modalities—including cannabis, opioids, physical therapy, and other adjuncts—rather than
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
